Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

upplies

associated with the company's clinical trials and research initiatives,

were $12.6 million, down from $13.9 million in the previous quarter and

up from $7.9 million in the fourth quarter of 2006. The decrease in R&D

expenses between the third and fourth quarters of 2007 is primarily

attributable to an increase in VEC-162 Phase III chronic insomnia

clinical trial costs being offset by a non-recurring third quarter

milestone charge of $5.0 million for the Fiapta(TM) NDA submission in

September 2007. The increase in R&D expenses in the fourth quarter of

2007 relative to the fourth quarter of 2006 is primarily attributable

to the same VEC-162 Phase III chronic insomnia clinical trial that was

initiated in late 2007. For the full year of 2007, total R&D expenses

were $47.2 million, down from $52.1 million in the full year of 2006.

Lower R&D expenses in 2007 resulted from the substantial completion of

the Fiapta(TM) Phase III clinical program in 2006.

General and administrative (G&A) expenses totaled $9.5 million in the

fourth quarter of 2007, down slightly from $9.6 million in the third

quarter of 2007, and up from $4.5 million in the fourth quarter of

2006. The increase in G&A expenses in the fourth quarter of 2007

relative to the fourth quarter of 2006 is primarily due to increased

Fiapta(TM) pre-launch commercial activities, stock-based compensation

charges, salaries and related costs of non-R&D personnel, insurance and

facility expenses. For the full year of 2007, total G&A expenses were

$32.8 million, up from $13.6 million in the prior year. The increase

in G&A expenses is primarily due to increased salaries, benefits and

stock-based compensation expense, increased business and commercial

development expenses, and higher insu
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
(Date:12/24/2014)... -- Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ) ... Application (CTA) with the United Kingdom,s ... approval to initiate clinical trials for the continued development ... on the Company receiving CTA regulatory approval, the Company ... the safety, tolerability and dose escalation of Anatabine Citrate ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2
... Human,Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) ("HPS" ... and the year ended,December 31, 2007. For the three ... a 6% decrease from revenues of $412,000,in the prior ... ($.01 per,share) as compared with a net income of ...
... Genaera,Corporation (Nasdaq: GENR ) today announced its financial ... net loss for the year ended,December 31, 2007 was $15.7 ... a net loss of $21.2 million, or $(1.46) per share,basic ... net loss for,the quarter ended December 31, 2007 was $5.8 ...
... (Nasdaq: NXTM ), a leading manufacturer of ... joined the Company as Senior,Vice President of Manufacturing ... responsible for all of NxStage,s manufacturing operations,including the ... NxStage with more than 20 years of operational,management ...
Cached Biology Technology:Human Pheromone Sciences Announces Quarterly and Full Year Results 2Human Pheromone Sciences Announces Quarterly and Full Year Results 3Human Pheromone Sciences Announces Quarterly and Full Year Results 4Genaera Corporation Announces 2007 Financial Results 2Genaera Corporation Announces 2007 Financial Results 3Genaera Corporation Announces 2007 Financial Results 4Genaera Corporation Announces 2007 Financial Results 5Genaera Corporation Announces 2007 Financial Results 6NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 2NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations 3
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... 9, 2014  Valencell, a leader in performance biometric ... staggering demand from its licensees for highly accurate, clinically ... not solely coming from fitness and health sectors, but ... "A wearable is only as useful as the biometric ... ultimate driver in long-term mass consumer adoption of wearable ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... Brian Chen has been awarded a prestigious Sloan Research ... Formation, investigates a big subject: deciphering the assembly instructions ... neural circuits wire up with precision. One of the ... the correct synaptic contacts during its development when faced ...
... named Brontomerus mcintoshi , or "thunder-thighs" after its enormously powerful ... is described in a paper recently published in the journal ... the U.K. and the U.S. A member of the ... Brachiosaurus , Brontomerus may have used its powerful ...
... the crowd? Is that all I,ll ever be? ... Do you ... the Crowd" It may seem paradoxical, but being ... UCLA life scientists. Biologists Kimberly Pollard and Daniel ... alarm-call vocalizations in eight species of rodents that live in social ...
Cached Biology News:Prestigious Sloan Fellowship awarded 2New 'thunder-thighs' dinosaur discovered 2New 'thunder-thighs' dinosaur discovered 3Even in a crowd, you remain unique, UCLA life scientists report 2
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
... raised against a partial recombinant NFKBIB. ... 145 a.a) partial recombinant protein with GST tag. ... Accession: BC015528 ... OMIM: 604495, GeneID: ...
... Perm/Wash Buffer I can be used in ... to permeabilize cells and to serve as ... Because saponin-mediated cell permeabilization is a reversible ... cells in the presence of saponin during ...
Mouse monoclonal antibody raised against a partial recombinant ACTN4. NCBI Entrez Gene ID = ACTN4...
Biology Products: